Login to Your Account



Pharma: Other News To Note


Monday, September 10, 2012
• Janssen Research & Development LLC, of Raritan, N.J, a unit of Johnson & Johnson, said it submitted a complete response to the FDA for the use of anticoagulant Xarelto (rivaroxaban) to reduce the risk of secondary cardiovascular events in patients with acute coronary syndrome (ACS), and also resubmitted its supplemental new drug application for Xarelto to reduce the risk of stent thrombosis in patients with ACS.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription